– Study Results Highlight Potential Utility of Targeting Mannose 6-Phosphate Pathway to Treat Multiple Lysosomal Storage Disorders – ST. LOUIS, Mo., – February 11, 2022 – M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation enzyme replacement and gene therapies for lysosomal storage disorders (LSDs), today announced the presentation of promising preclinical …
Continue readingM6P Therapeutics to Participate in Key Event Highlights at WORLDSymposium™ 2022 and Present Preclinical Data Across Multiple Lysosomal Diseases
– M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company Co-founder of M6PT, Dr. Stuart Kornfeld, to receive the 2022 Roscoe O. Brady Award for Innovation and Accomplishment – – Preclinical data across three lysosomal disorders demonstrate the broad potential of the Company’s therapies developed under its novel S1S3 co-expression technology platform …
Continue readingUpdate from Mucolipidosis Collaborative Network (MCRN) and Cure Mucolipidosis (Cure ML) on Mucolipidosis Type II
The Mucolipidosis Collaborative Network (MCRN) and Cure Mucolipidosis (Cure ML) announced that they will be able to initiate the Natural History studies on a model of mucolipidosis type II (ML II) in 2022. M6PT met with both the MCRN and Cure ML to provide an update on the status of M6PT’s preclinical development programs for …
Continue readingM6P Therapeutics to Present at the 17th Annual International Congress on Neuronal Ceroid Lipofuscinosis
ST. LOUIS, Mo., – October 8, 2021 – M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced the Company’s participation at the 17th International Congress on Neuronal Ceroid Lipofuscinosis (NCLs), or NCL2021, being held from October 6-10, 2021, …
Continue readingDr. Stuart Kornfeld, M6P Therapeutics’ Co-Founder, to Receive the Roscoe O. Brady Award For Innovation and Accomplishment at WORLDSymposium™ 2022
– The Roscoe O. Brady Award is granted to individuals for their substantial body of innovation and achievement in the field of lysosomal storage disorder (LSDs) research and therapy – ST. LOUIS, Mo., – September 30, 2021 – M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for …
Continue readingM6P Therapeutics Presented Data on M041, A Recombinant Enzyme Therapy, for the Treatment of Sanfilippo B Syndrome at MPS 2021
– Preclinical data provide proof of concept for recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) demonstrating improved mannose 6-phosphorylation – – Leveraging the Company’s proprietary S1S3 bicistronic expression platform, M041 is co-expressed human NAGLU and S1S3, resulting in NAGLUM6P – – With increased efficiency to phosphorylate lysosomal enzymes, M041 is a potential novel recombinant enzyme therapy for Sanfilippo B …
Continue readingM6P Therapeutics Announces Presentation at the Upcoming 16th International Symposium of MPS and Related Diseases
– Oral Presentation on Friday, July 23, 2021 @ 11:25 a.m. ET / 17:25 p.m. CEST – ST. LOUIS, Mo., – July 21, 2021 – M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), announced today its participation at the 16th International Symposium of MPS …
Continue readingM6P Therapeutics to Host Key Opinion Leader Webinar on Lysosomal Storage Disorders
– Webinar on Wednesday, July 28 @ 10 a.m. ET – ST. LOUIS, Mo., – July 19, 2021 – M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced that it will host a key opinion leader (KOL) webinar on LSDs on …
Continue readingM6P Therapeutics to Participate in Upcoming Fireside Chat Discussing the Company’s First-in-Class Platform for Lysosomal Enzyme and Gene Delivery at the ROTH Virtual Private Company Forum
– Discussion to include progress and innovations in next-generation therapies for the treatment of lysosomal storage disorders – ST. LOUIS, Mo., – June 25, 2021 – M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced that Pawel Krysiak, M6PT’s president and …
Continue readingM6P Therapeutics Presents M002 Gene Therapy Preclinical Proof-of-Concept Data for the Treatment of Mucolipidosis Type II at the ASGCT 24th Annual Meeting
– Preclinical data provide proof of concept for M002 to restore cellular uptake and lysosomal delivery and attenuate phenotype in mouse models of mucolipidosis type II – – M002 leverages the Company’s proprietary S1S3 bicistronic platform technology in an AAV9 gene therapy to restore mannose 6-phosphate recognition marker on lysosomal enzymes – ST. LOUIS, Mo., …
Continue reading